Markets:

Overview

News

Currencies

International

Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

1,025.00 +32.01 (+3.22%)

Streaming Delayed Price Updated: 10:43 AM EDT, Aug 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗

October 03, 2023

Via Benzinga

Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review ↗

September 29, 2023

But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus.

Via Investor's Business Daily

What's Going On Pfizer's Subsidiary Biohaven Stock? ↗

September 27, 2023

Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an

Via Benzinga

Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29% ↗

September 27, 2023

The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases.

Via Investor's Business Daily

Why Immunovant Stock Is Bolting Higher Today ↗

September 27, 2023

The company may have best-in-class autoimmune disease therapy under its roof.

Via The Motley Fool

The Latest Analyst Ratings for argenx ↗

September 18, 2023

Via Benzinga

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗

September 15, 2023

Via Benzinga

What 20 Analyst Ratings Have To Say About argenx ↗

August 31, 2023

Via Benzinga

Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering ↗

September 27, 2023

Both companies are working on drugs that lower an antibody tied to numerous autoimmune conditions.

Via Investor's Business Daily

Immunovant Soars 73% — And Slugs Argenx — As Autoimmune Disease Battle Heats Up ↗

September 26, 2023

Immunovant is hoping to come up with the best drug in its class, lowering a key antibody tied to autoimmune diseases.

Via Investor's Business Daily

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Via MarketBeat

argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

September 21, 2023

From argenx SE

Via GlobeNewswire

This New S&P 500 Entrant Leads 5 Stocks Near Buy Points ↗

September 16, 2023

These stocks could lead if the market rallies.

Via Investor's Business Daily

Topics Stocks

Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today ↗

August 30, 2023

Via Benzinga

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗

August 10, 2023

Via Benzinga

argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

September 15, 2023

From argenx SE

Via GlobeNewswire

argenx to Present at Upcoming Investor Conferences

August 30, 2023

From argenx SE

Via GlobeNewswire

Top AI Stock ANET Leads 5 Stocks Near Buy Points In Tough Market ↗

August 19, 2023

Arista Networks and Dutch biotech Argenx lead this weekend's watch list.

Via Investor's Business Daily

Topics Artificial Intelligence

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗

July 31, 2023

Via Benzinga

Is Argenx Stock a Buy Now? ↗

July 31, 2023

Good news keeps rolling in for the biotech.

Via The Motley Fool

Earnings Outlook For argenx ↗

July 26, 2023

Via Benzinga

argenx Unusual Options Activity ↗

July 21, 2023

Via Benzinga

Why Shares of Argenx Jumped This Week ↗

July 21, 2023

The company's lead therapy showed progress in treating an autoimmune disorder.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023 ↗

July 31, 2023

Via Benzinga

argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update

July 27, 2023

From argenx SE

Via GlobeNewswire

Argenx Stock Rides 'Megabuster' Drug Excitement To 40% Gain Before Earnings ↗

July 26, 2023

Argenx is up around 40% in 2023 after shares soared nearly 30% in a single day last week.

Via Investor's Business Daily

argenx announces closing of global offering

July 24, 2023

From argenx SE

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023 ↗

July 24, 2023

Via Benzinga

Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review ↗

July 21, 2023

But all the major indexes are at or near 15-month highs.

Via Investor's Business Daily

Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade ↗

July 20, 2023

On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81.

Via Investor's Business Daily

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.